Navigation Links
New Strategy to Counter Problem Drinking

Problem drinkers who took a craving-curbing drug whenever they felt the desire to imbibe reported fewer heavy drinking days each month than drinkers who took a look-alike placebo pill, but both groups reported marked reductions in heavy drinking days.

Those findings come from a study of 403 heavy drinkers in Finland, who took either a placebo or the drug nalmefene on an as needed basis.

It has a robust and sustained effect in reducing harmful heavy drinking in a large study population, said researcher Sakari Karhuvaara. Alcohol problems have huge negative impacts on the well-being of individuals and families and cause enormous costs to society due to lost working days, accidents, treatment of alcohol-related disease, etcetera.

Before the study, patients assigned to nalmefene treatment reported 15.5 average heavy drinking days each month. They were directed to take the drug whenever they felt a looming urge to drink. During the first three months of treatment, the average number of heavy drinking days was 8.6 to 9.3 for the people in the nalmefene group.

The drinkers assigned to the placebo group had somewhat less dramatic reductions. They averaged 16.2 heavy drinking days a month before the study and 10.6 to 12.0 during the trial.

Researchers double-checked participant-reported alcohol consumption changes with tests that measured alcohol-use biomarkers in the blood.

In the United States, abstinence has been the traditional goal of the treatment of alcohol dependence, but in the last 20 years, there has been a movement to consider harm reduction or drinking reduction as a goal equal to abstinence.

Alcohol dependence is nowadays recognized as a chronic, recurring disorder where relapses almost inevitably occur during and after the treatment, Karhuvaara said. So focusing on harm reduction in the short term is often much more feasible than complete abst inence, he added.

Karhuvaara is a physician and health researcher who was once an employee of Biotie Therapies Corp., the manufacturer of nalmefene. The drug maker supported the new study.

There are fair amounts of good data (showing) that the more drinks you have a day, the more likely you are to have health or social consequences, said alcohol researcher Raymond Anton.

The thinking is that if you can reduce heavy drinking days or the number of drinks per drinking day, you might actually alleviate some suffering, even though you dont cause the person to be abstinent.

Not everyone who seeks alcohol treatment is ready to consider a lifetime without alcohol, so an abstinence goal can be a barrier for some people considering help.

Many health professionals are convinced that a harm reduction approach can draw more people into treatment, said Anton, director of the Center for Drug and Alcohol Programs at the Medical University of South Carolina. Anton did not participate in the Finnish study, but he has conducted nalmefene research in the United States.

The Finnish researchers note some side effects among people in the nalmefene group, including nausea, abdominal discomfort, as well as energy and sleep difficulties. However, most study participants remained in the trial and continued using the drug.

I wish theyd done an analysis to see if the people who suffered those side effects were the same people who drank less. Perhaps some of the reduction in drinking may have been because they didnt feel so good, rather than because the drug just took away an urge to drink, Anton said.

Patients must take most medications for alcohol treatment daily. Nalmefene taken as needed fits into the harm reduction treatment approach.

The drug is an opioid antagonist that works to block the effects of endorphins. The U.S. Food and Drug Administrat ion has not approved nalmefene for use in alcohol treatment; the drug is primarily available in investigational studies.

Karhuvaara said his study also suggests that practically any doctor could successfully administer nalmefene in a wide variety of medical settings.

It is an attempt to get the drug out of the sole use of addiction specialists and into the hands of primary providers, Anton said.


Related medicine news :

1. Novel Strategy To Combat Alzheimer’s Disease
2. "Defensive Pessimism" Before Exam Results Not a Good Strategy
3. WHO Devises New Global Strategy To Fight Tuberculosis
4. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
5. West Nile Virus Can Be Tackled By New Strategy
6. Australia Set To Implement A national Strategy Tackle Cannabis Abuse
7. Clement Urged to Plot a National Pharmaceutical Strategy
8. New Preventive Strategy to Fight Childhood Obesity
9. Rae unveils Health-care Strategy
10. A Promising New Vaccination Strategy for Late-Stage Melanoma
11. Effective Strategy Against Bird flu-Spainish Flu Vaccine Raises Hopes
Post Your Comments:

(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology: